Scleroderma

What is Scleroderma?

Scleroderma, also known as systemic sclerosis (SSc), is a rare autoimmune connective tissue disorder characterized by widespread fibrosis (scarring) of the skin and internal organs. The condition occurs when the immune system mistakenly attacks healthy tissues, leading to excessive collagen production that causes skin thickening and organ dysfunction. Scleroderma primarily affects women between ages 30-50, though it can occur at any age. With an estimated prevalence of 7-489 cases per million people worldwide, scleroderma is classified as a rare disease (ORPHA code 90291).

Key statistics

Statistic	Value
Global prevalence	7-489 per million people
Female-to-male ratio	4-5:1
Peak age of onset	30-50 years
10-year survival rate	85-90% (varies by subtype)

Symptoms

Summary: Skin thickening, Raynaud’s phenomenon, joint pain, heartburn, shortness of breath, fatigue, digital ulcers, muscle weakness, dry eyes and mouth.

Early symptoms often include Raynaud’s phenomenon (fingers and toes turning white, blue, then red in response to cold or stress), fatigue, and joint stiffness. Skin changes typically begin with puffy, swollen fingers and hands.

Common symptoms include progressive skin thickening and tightening, particularly on fingers, hands, face, and arms. Patients frequently experience gastroesophageal reflux, joint pain and stiffness, muscle weakness, and dry eyes or mouth. Difficulty swallowing and changes in facial appearance due to skin tightening are also typical.

Serious complications may develop as the disease progresses, including pulmonary fibrosis (lung scarring), pulmonary arterial hypertension, kidney crisis with severe hypertension, heart problems including arrhythmias and heart failure, and severe gastrointestinal complications. Digital ulcers on fingertips can become infected and lead to tissue death.

Causes and risk factors

Scleroderma is an autoimmune disorder with unknown exact causes, likely involving a complex interaction of genetic predisposition, environmental triggers, and immune system dysfunction. The disease is not directly inherited, but genetic factors contribute to susceptibility.

Risk factors include female gender, age between 30-50 years, certain genetic markers (HLA associations), exposure to silica dust, organic solvents, or certain medications. Some studies suggest viral infections, including cytomegalovirus and parvovirus B19, may trigger the disease in genetically susceptible individuals. Occupational exposures to silicone, vinyl chloride, and certain chemotherapy drugs have been associated with increased risk.

Prevention

Currently, there is no known way to prevent scleroderma. However, early detection through recognition of initial symptoms like Raynaud’s phenomenon and specific autoantibody testing can help families and physicians make informed decisions about monitoring and early intervention.

Risk reduction strategies include avoiding known environmental triggers such as silica dust exposure, limiting exposure to organic solvents, and protecting hands and feet from cold temperatures. Regular health screenings for at-risk individuals with family history or early symptoms can facilitate prompt diagnosis and treatment initiation.

Complications

Without proper treatment and monitoring, scleroderma can lead to life-threatening complications. Pulmonary complications include interstitial lung disease (affecting 70-80% of patients) and pulmonary arterial hypertension, which are leading causes of mortality.

Renal crisis occurs in 5-10% of patients, typically within the first few years of disease onset, characterized by sudden severe hypertension and kidney failure. Cardiac complications include conduction abnormalities, heart failure, and pericardial disease. Gastrointestinal complications range from severe reflux and difficulty swallowing to intestinal malabsorption and bacterial overgrowth. Severe digital ischemia can lead to amputation of fingertips.

Diagnosis

Diagnosis relies on clinical criteria established by the American College of Rheumatology and European League Against Rheumatism (ACR/EULAR), including skin thickening and characteristic features like digital ulcers, telangiectasias, and abnormal nailfold capillaroscopy.

Laboratory tests include antinuclear antibody (ANA) testing, with specific patterns including anti-centromere, anti-Scl-70 (topoisomerase I), and anti-RNA polymerase III antibodies. Complete blood count, comprehensive metabolic panel, and inflammatory markers help assess organ involvement.

Imaging studies include high-resolution computed tomography (HRCT) of the chest to evaluate lung involvement, echocardiography to assess pulmonary pressures and heart function, and barium swallow studies for gastrointestinal evaluation. Nailfold capillaroscopy reveals characteristic microvascular changes.

Treatment

Treatment is organ-specific and symptomatic, as no cure currently exists. For skin involvement, methotrexate and mycophenolate mofetil may slow progression in early disease.

Pulmonary complications are treated with cyclophosphamide or mycophenolate mofetil for interstitial lung disease. Pulmonary arterial hypertension requires specialized medications including bosentan, sildenafil, or epoprostenol.

Raynaud’s phenomenon is managed with calcium channel blockers like nifedipine or amlodipine. Severe cases may require iloprost infusions. Gastrointestinal symptoms are treated with proton pump inhibitors, prokinetic agents, and antibiotics for bacterial overgrowth. Renal crisis requires immediate treatment with ACE inhibitors, particularly captopril.

Prognosis

Prognosis varies significantly by disease subtype and organ involvement. Patients with limited cutaneous systemic sclerosis generally have better outcomes, with 10-year survival rates of 90-95%. Diffuse cutaneous disease carries a more serious prognosis, with 10-year survival of 70-80%.

Prognostic factors include extent of skin involvement, presence of specific antibodies, and early organ complications. Anti-RNA polymerase III antibodies associate with higher renal crisis risk, while anti-Scl-70 antibodies correlate with increased lung involvement. Early diagnosis and appropriate treatment significantly improve outcomes and quality of life.

Quality of life

Living with scleroderma requires comprehensive lifestyle adjustments and ongoing self-management. Daily care includes protecting hands and feet from cold exposure through heated gloves, warm clothing, and avoiding air conditioning. Regular skin care with moisturizers helps manage tightness and prevents cracking.

Exercise should focus on maintaining flexibility and joint mobility through stretching, range-of-motion exercises, and low-impact activities like swimming or walking. Physical therapy can help maintain function and prevent contractures.

Dietary modifications include eating small, frequent meals to manage reflux, avoiding acidic and spicy foods, and staying upright after eating. Nutritional support may be necessary if malabsorption develops.

Mental health support is crucial, as depression and anxiety are common. Support groups, counseling, and stress management techniques can significantly improve coping. Occupational modifications may include ergonomic adjustments, flexible scheduling, and workplace accommodations for medical appointments.

Pregnancy and fertility

Scleroderma can impact pregnancy outcomes, requiring careful planning and specialized monitoring. Women with stable, limited disease generally have successful pregnancies, while those with active diffuse disease or significant organ involvement face higher risks.

Pregnancy considerations include increased risk of preterm birth, low birth weight, and preeclampsia. Renal crisis risk may be elevated during pregnancy. Many medications require modification or discontinuation, including mycophenolate mofetil and methotrexate, which are teratogenic.

Genetic counseling should address the low but present familial clustering risk and discuss inheritance patterns. Fertility is generally not significantly affected, though severe disease may impact overall health and pregnancy capacity.

Children

Pediatric scleroderma is rare but presents unique challenges. Juvenile systemic sclerosis often differs from adult disease, with higher likelihood of overlap syndromes and different antibody profiles.

Growth and development may be affected by chronic inflammation, medication effects, and nutritional issues. School accommodations may be necessary for fatigue, joint pain, and medical appointments. Physical therapy and occupational therapy are particularly important to maintain growth and function.

Transition to adult care should begin in adolescence, with gradual transfer of disease management responsibilities and introduction to adult rheumatology teams. Psychosocial support is crucial during this vulnerable period.

When to see a doctor

Immediate medical attention is required for sudden severe headache with high blood pressure (possible renal crisis), severe shortness of breath, chest pain, or signs of heart failure including swelling and difficulty breathing.

Urgent evaluation is needed for new or worsening digital ulcers, signs of infection, progressive difficulty swallowing, or significant changes in skin tightness or color. New onset of Raynaud’s phenomenon after age 40, particularly with abnormal capillaroscopy or positive autoantibodies, warrants prompt rheumatologic evaluation.

Regional context

Limited specific data exists regarding scleroderma prevalence in the Caucasus region (Georgia, Armenia, Azerbaijan). Some studies suggest regional variations in disease prevalence and autoantibody patterns, possibly related to genetic factors and environmental exposures specific to different populations.

GMJ welcomes contributions from regional researchers to build the evidence base for scleroderma in the Caucasus, particularly regarding local prevalence, genetic factors, environmental triggers, and healthcare access challenges.

Research and clinical trials

Current research focuses on understanding disease mechanisms, developing targeted therapies, and improving early diagnosis. Promising areas include antifibrotic therapies, stem cell transplantation for severe cases, and biomarker development for predicting organ involvement.

Recent breakthroughs include the approval of nintedanib for scleroderma-associated interstitial lung disease and ongoing trials of novel antifibrotic agents. Autologous stem cell transplantation shows promise for severe, progressive disease.

ClinicalTrials.gov lists numerous ongoing studies investigating new treatments, biomarkers, and disease mechanisms. Patients should discuss clinical trial participation with their rheumatology team.

Frequently asked questions

Is scleroderma hereditary?

Scleroderma is not directly inherited, but genetic factors contribute to disease susceptibility. The risk of developing scleroderma is slightly higher in family members, but most cases occur without family history.

Can scleroderma be cured?

Currently, there is no cure for scleroderma. However, early diagnosis and appropriate treatment can significantly slow disease progression, manage symptoms, and prevent complications, leading to improved outcomes and quality of life.

Will my scleroderma get worse over time?

Disease progression varies widely between individuals. Some patients experience stable disease for years, while others may have periods of progression followed by stability. Regular monitoring and early treatment of complications can help maintain function.

Can I have a normal pregnancy with scleroderma?

Many women with stable, limited scleroderma have successful pregnancies. However, pregnancy requires specialized monitoring and may involve increased risks. Pre-pregnancy counseling with both rheumatology and high-risk obstetric teams is essential.

Should I avoid certain activities or foods?

Avoiding cold exposure and protecting hands and feet is important for managing Raynaud’s phenomenon. Dietary modifications to manage reflux include small, frequent meals and avoiding acidic or spicy foods. Regular exercise and physical therapy help maintain flexibility and function.

Support and resources

International organizations:
– Scleroderma Foundation (scleroderma.org)
– Scleroderma & Raynaud’s UK (sruk.co.uk)
– EURORDIS (eurordis.org)
– National Organization for Rare Disorders – NORD (rarediseases.org)
– Orphanet (orpha.net)
– World Health Organization Rare Disease Portal (who.int)

Medical databases:
– Online Mendelian Inheritance in Man – OMIM (omim.org)
– GeneReviews (ncbi.nlm.nih.gov/books/NBK1116)

Related conditions

– Systemic lupus erythematosus – Another systemic autoimmune connective tissue disorder with overlapping features
– Mixed connective tissue disease – Overlap syndrome sharing features of multiple autoimmune conditions
– Dermatomyositis – Inflammatory muscle disease that can overlap with scleroderma
– Primary Raynaud’s phenomenon – Isolated vascular condition without underlying autoimmune disease
– Eosinophilic fasciitis – Rare condition causing skin and fascia thickening similar to scleroderma

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, UpToDate, relevant EULAR/ACR/WHO guidelines. This article is for informational purposes only and does not constitute medical advice. Content licensed under CC BY 4.0.

Sources: Orphanet (orpha.net), OMIM, GeneReviews (NCBI), WHO ICD-11, EULAR/ACR guidelines. Schema.org MedicalCondition structured data included.